Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Policy / Regulatory

NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company

Sanofi’s Q2 2024 Results Showcase Robust Growth in Pharma and Consumer Health Divisions

Fineline Cube Jul 25, 2024

Sanofi (NASDAQ: SNY; EPA: SAN), the French multinational pharmaceutical company, has reported its financial results...

Company Deals

Agilent Technologies and Shanghai Majorbio Bio-pharm Ink Deal to Transform Life Science Research in China

Fineline Cube Jul 25, 2024

Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets,...

Company Deals

Nanjing Sanhome Pharmaceutical and China Resource Pharma Deepen Collaboration for Market Expansion

Fineline Cube Jul 25, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd, a Chinese pharmaceutical company, and China Resource Pharmaceutical Commercial Group...

Company Drug

Jiangsu Suzhong Pharma’s Sutetinib Earns Breakthrough Designation for NSCLC from China’s NMPA

Fineline Cube Jul 25, 2024

Jiangsu Suzhong Pharma Group Co., Ltd, a leading pharmaceutical company based in China, has received...

Company Deals Medical Device

Edwards Lifesciences to Acquire Peijia Medical’s US Partner JenaValve, Impact on Licensing Deal Minimal

Fineline Cube Jul 25, 2024

China-based Peijia Medical Ltd (HKG: 9996) has announced that its US-based partner JenaValve Technology Inc....

Company Deals

RemeGen Scales Back Private Placement to Fund New Drug R&D

Fineline Cube Jul 25, 2024

RemeGen (HKG: 9995), a biopharmaceutical company based in China, has revised its private placement plan,...

Policy / Regulatory

China’s NMPA Suspends Daewoong Bio’s Antibiotic, Excludes Firm from National Procurement Program

Fineline Cube Jul 25, 2024

The National Medical Products Administration (NMPA) in China has taken a decisive step to suspend...

Company Drug

Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Cleared for Clinical Trial by NMPA

Fineline Cube Jul 25, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Drug

Hinova Pharmaceuticals Receives NMPA Approval to Test Myelofibrosis Drug Candidate HP560

Fineline Cube Jul 25, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biopharmaceutical company based in Chengdu, has announced that it...

Company Drug

Belief BioMed and Takeda’s Hemophilia B Gene Therapy BBM-H901 Accepted for NMPA Review

Fineline Cube Jul 25, 2024

Belief BioMed Group (BBM), a Shanghai-based gene therapy specialist, and Takeda have announced that the...

Company Deals

Pinetree Therapeutics Strikes EGFR Degrader Deal with AstraZeneca Worth Over USD 500 Million

Fineline Cube Jul 25, 2024

Pinetree Therapeutics Inc., a Massachusetts-based biotechnology company, has announced the signing of an exclusive option...

Company Deals

Novartis Partners with Dren Bio to Develop Next-Generation Cancer Therapies

Fineline Cube Jul 25, 2024

Novartis (NYSE: NVS), a leading Swiss pharmaceutical company, has entered into a strategic collaboration with...

Company Drug

Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study

Fineline Cube Jul 25, 2024

Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the...

Company Drug

Novo Nordisk’s Wegovy Approved in the UK to Reduce Cardiovascular Risks in Overweight Adults

Fineline Cube Jul 24, 2024

Novo Nordisk (NYSE: NVO)’s anti-obesity drug Wegovy (semaglutide) has received a new indication approval in...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Receives FDA IND Approval for Multiple Sclerosis

Fineline Cube Jul 24, 2024

China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...

Company Drug

ST Phi Therapeutics’ Universal Cell Therapy for Solid Tumors Gets Green Light for Clinical Trial in China

Fineline Cube Jul 24, 2024

ST Phi Therapeutics, a Hangzhou-based cell therapy specialist, has secured tacit approval from China’s National...

Company

Shanghai Rightongene Biotechnology Co., Ltd Executives Under Investigation by Chinese Authorities

Fineline Cube Jul 24, 2024

Shanghai Rightongene Biotechnology Co., Ltd (SHA: 688217), a Chinese biopharmaceutical company, has announced that key...

Company Medical Device

Hangzhou Jianjia Medical’s Arthbot Surgical Robot Receives NMPA Approval for Orthopedic Procedures

Fineline Cube Jul 24, 2024

Hangzhou Jianjia Medical Technology Co., Ltd has received marketing approval from China’s National Medical Products...

Company Drug

Innorna’s Herpes Zoster mRNA Vaccine IN001 Receives Clinical Trial Approval in China

Fineline Cube Jul 24, 2024

Shenzhen-based Innorna Co., Ltd has announced that it has received approval from the National Medical...

Company

BeiGene Launches Flagship US Facility in New Jersey to Expand Oncology R&D and Manufacturing

Fineline Cube Jul 24, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a global biotechnology company, has announced the inauguration...

Posts pagination

1 … 370 371 372 … 711

Recent updates

  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
  • NMPA Issues 108th Batch Catalog of Reference Listed Drugs for Generic Drugs, Adding 17 New Specifications
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Company

InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.